补肾强督清化汤治疗强直性脊柱炎肾虚湿热证临床疗效评估
Clinical efficacy evaluation of Qiangdu Qinghua Decoction in treating ankylosing spondylitis with kidney deficiency and damp heat syndrome
- 北京中医药 2022年41卷第8期 页码：838-843
- 作者机构：
1.北京中医药大学，北京100029
2.中国中医科学院，北京100700
3.中日友好医院中医风湿病科 免疫炎性;疾病北京市重点实验室，北京100029
- 作者简介：
穆闻君，女，26岁，硕士研究生。研究方向：中医药诊治风湿病。
孔维萍，E-mail：kongweiping75@126.com
- 基金信息：北京市中医药科技发展资金项目(JJ-2020-87)
DOI：10.16025/j.1674-1307.2022.08.003
中图分类号：
扫 描 看 全 文
穆闻君，孙文婷，胡丽芳，等.补肾强督清化汤治疗强直性脊柱炎肾虚湿热证临床疗效评估［J］.北京中医药，2022，41（8）：838-843.
MU Wen-jun,SUN Wen-ting,HU Li-fang,et al.Clinical efficacy evaluation of Qiangdu Qinghua Decoction in treating ankylosing spondylitis with kidney deficiency and damp heat syndrome[J]. Beijing Journal of Traditional Chinese Medicine,2022,41(08):838-843.
穆闻君，孙文婷，胡丽芳，等.补肾强督清化汤治疗强直性脊柱炎肾虚湿热证临床疗效评估［J］.北京中医药，2022，41（8）：838-843. DOI： 10.16025/j.1674-1307.2022.08.003.
MU Wen-jun,SUN Wen-ting,HU Li-fang,et al.Clinical efficacy evaluation of Qiangdu Qinghua Decoction in treating ankylosing spondylitis with kidney deficiency and damp heat syndrome[J]. Beijing Journal of Traditional Chinese Medicine,2022,41(08):838-843. DOI： 10.16025/j.1674-1307.2022.08.003.
摘要
目的,2,探讨补肾强督清化汤治疗强直性脊柱炎（AS）肾虚湿热证临床疗效。,方法,2,采用单盲、随机对照的研究方法，将70例AS肾虚湿热证患者按随机数字表法分为观察组和对照组。观察组予补肾强督清化汤联合塞来昔布治疗，对照组予中药安慰剂联合塞来昔布治疗，疗程均为12周。评价2组患者治疗前后临床症状及体征、中医证候评分、疾病活动度、炎症反应指标，采用AS国际评估委员会的工作小组（ASAS）制定的疗效标准评价体系，即ASAS20、ASAS40、ASAS5/6，Bath AS活动性指数50（BASDAI50）和中医证候评分改善率评估补肾强督清化汤的临床疗效。,结果,2,治疗12周后观察组与对照组ASAS20应答率分别为73.5%、44.1%；ASAS40应答率分别为47.1%、17.6%；ASAS5/6应答率分别为52.9%、23.5%；中医总有效率分别为91.88%、55.88%，上述指标2组差异有统计学意义（,P,<,0.05）。治疗后2组AS患者综合指数（BAS-G）、BASDAI、疾病活动评分-C反应蛋白指标（ASDAS-CRP）、Bath功能指数（BASFI）、夜间痛VAS评分、脊柱痛VAS评分、中医证候评分及实验室指标等与治疗前相比均显著改善，差异有统计学意义（,P,<,0.05）；组间比较，观察组BAS-G、BASDAI、BASFI、ASDAS-CRP、夜间痛、中医证候评分均优于对照组，差异有统计学意义（,P,<,0.05）。,结论,2,补肾强督清化汤治疗AS肾虚湿热证，临床疗效显著，优于单纯使用塞来昔布，且不良反应少，安全性高。
Abstract
Objective,2,To investigate the clinical efficacy of Bushen Qiangdu Qinghua Decoction on ankylosing spondylitis （AS） of kidney deficiency and dampness heat syndrome.,Methods,2,Using a single-blind， randomized controlled study method， 70 patients with kidney deficiency and dampness heat syndrome of AS were randomly divided into observation and control groups according to random number table method. The observation group was treated with Bushen Qiangdu Qinghua Decoction combined with celecoxib， while the control group was treated with Chinese herbal medicine placebo combined with celecoxib. The course of treatment was 2 weeks for both groups. The clinical symptoms and signs， TCM symptom scores， disease activity， inflammatory response indexes of the two groups were evaluated before and after the treatment， and the clinical efficacy of Bushen Qiangdu Qinghua Decoction was assessed using the evaluation system of efficacy criteria developed by the working group of AS International Assessment Committee （ASAS）， namely ASAS20， ASAS40， ASAS5/6， BASDAI50 and the improvement rate of TCM symptom scores.,Results,2,After 12 weeks of treatment，the ASAS20 response rate was 73.5% and 44.1% in the observation group and the control group respectively； ASAS40 response rate was 47.1% and 17.6% respectively； ASAS5/6 response rate was 52.9% and 23.5% respectively； the total TCM effective rate was 91.88% and 55.88% respectively， and the differences of above indexes between the two groups were statistically significant （,P,<,0.05）. After treatment， BAS-G， BASDAI， ASDAS-CRP， BASFI， nocturnal pain VAS score， spinal pain VAS score， TCM evidence score， laboratory index of AS patients in both groups were significantly improved compared with those before treatment， and the differences were statistically significant （,P,<,0.05）； compared two groups， BAS-G， BASDAI， ASDAS-CRP nocturnal pain， TCM symptoms scores in the observation group were better than those in the control group， and the differences were statistically significant （,P,<,0.05）.,Conclusion,2,The clinical efficacy of Bushen Qiangdu Qinghua Decoction in the treatment of AS with kidney deficiency and dampness heat syndrome is significantly better than that of celecoxib with less adverse effects and high safety.
关键词
补肾强督清化汤强直性脊柱炎肾虚湿热证疗效评价
Keywords
Bushen Qiangdu Qinghua Decoctionankylosing spondylitiskidney deficiency and dampness heat syndromeefficacy evaluation
references
中华医学会风湿病学分会.强直性脊柱炎诊断及治疗指南[J].中华风湿病学杂志,2010(8):557-559.
GARCIA-MONTOYA L,GUL H,EMERY P.Recent advances in ankylosing spondylitis: understanding the disease and management[J].F1000Res，2018,7:F1000 Faculty Rev-1512.
ZHANG Y,NING C,ZHOU H,et al.Interleukin-1β, interleukin-6,and interleukin-17A as indicators reflecting clinical response to celecoxib in ankylosing spondylitis patients[J].Ir J Med Sci，2021,190(2):631-638.
WEN JT,ZHANG DH,FANG PF,et al.Role of Th1/Th2 cytokines in the diagnosis and prognostic evaluation of ankylosing spondylitis[J].Genet Mol Res ,2017,16(1).doi: 10.4238/gmr16019322http://dx.doi.org/10.4238/gmr16019322. PMID: 28362980.
KÖMEL PIMENTA PR,RIBEIRO DA SILVA MR, RIBEIRO DOS SANTOS JB,et al.Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study[J].J Comp Eff Res，2021,10(6):509-517.
LI L,CHEN B,ZHAO H,et al.Bone changes and curative effect of infliximab in patients with ankylosing spondylitis[J].J Musculoskelet Neuronal Interact，2020,20(3):437-443.
王瑞瑞,金实,丁雪玲,等.温肾健脾定脊汤治疗强直性脊柱炎肾虚督亏、脾病湿困证的临床观察[J].中华中医药杂志,2020,35(4):2117-2119.
朱笑夏,金玥,陶庆文,等.补肾舒脊颗粒治疗肾虚督寒证强直性脊柱炎的临床疗效及对放射学进展的影响[J].中华中医药杂志,2020,35(1):464-468.
杨小纯,金玥,蔡悦.羌活胜湿汤加减方对强直性脊柱炎患者脊柱功能及急性时相反应物指标的影响[J].实用医学杂志,2021,37(18):2423-2427.
阎小萍,陶庆文,孔维萍,等.补肾强督法为主的综合疗法治疗强直性脊柱炎临床和实验系列研究[J].风湿病与关节炎,2012,1(3):10-18.
国家中医药管理局医政司.22个专业95个病种中医诊疗方案(合订版)[M].北京:国家中医药管理局医政司,2010:264-265.
孔维萍,金玥,朱笑夏,等.强直性脊柱炎寒热证候的脊柱结构损伤特点[J].中医杂志,2015,56(12):1026-1029.
孙文婷,郑丹妮,杨爱娟,等.男性强直性脊柱炎患者中医证型与骨密度关系及低骨密度危险因素分析[J].中国中医药信息杂志,2020,27(9):35-40.
陶庆文,徐愿,孔维萍,等.基于名老中医经验传承寒热辨治强直性脊柱炎的临床研究[J].世界中西医结合杂志,2013,8(7):730-733.
VAN DER LINDEN S,VALKENBURG HA,CATS A.Evaluation of diagnostic criteria for ankylosing spondylitis.A proposal for modification of the New York criteria[J].Arthritis Rheum，1984,27(4):361-368.
SIEPER J,RUDWALEIT M,BARALIAKOS X,et al.The Assessment of SpondyloArthritis international Society (ASAS) handbook:a guide to assess spondyloarthritis[J].Ann Rheum Dis，2009，68:ii1-ii44.
国家中医药管理局医政司.24个专业92个病种中医诊疗方案(2017年版)[M].北京:中国医药科技出版社,2017:1-8.
郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:119-123.
韩善夯,孙美秀,甘可,等.强直性脊柱炎中医证候分型与炎症相关性分析[J].中华中医药杂志,2019,34(12):5957-5959.
陈爱萍,路素言,邵培培,等.强直性脊柱炎入院患者寒热证候特点及其与脊柱损伤和疾病活动度关系研究[J].北京中医药,2018,37(5):440-442.
时圣明,袁永兵,兰新新,等.狗脊的化学成分及药理作用研究进展[J].药物评价研究,2016,39(3):489-492.
陈禹,孙志滢,杨宇纯,等.华泽兰花部位化学成分及其抑菌活性研究[J].天然产物研究与开发,2020,32(1):57-62.
雍晨,鲁璐,汪悦.基于网络药理学研究土茯苓的活性成分及药理机制[J].辽宁中医杂志,2019,46(9):1926-1930.
杨建宇,李杨,范竹雯,等.中国道地药材研究近况系列(9) 道地药材怀牛膝的研究近况[J].光明中医,2020,35(5):786-789.
张津萌,张华东,赵亚男,等.中医药改善强直性脊柱炎疾病活动度的Meta分析[J].北京中医药,2021,40(4):350-354.
0
浏览量
0
下载量
0
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备18046208号-2
京公网安备 11010102006710号 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies